What is the 13F Pro Quality Score for CNSY?

13F Pro ranks CERENOME, INC. (CNSY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CNSY's current score at https://13fpro.ai/company/CNSY (free sign-up required for the full ranking).

Where does 13F Pro source CNSY data?

All CERENOME, INC. fundamentals and ownership data come directly from SEC EDGAR. CERENOME, INC. files with the SEC under CIK 1095981. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CNSY in?

CERENOME, INC. (CNSY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CNSY research updated on 13F Pro?

CNSY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CERENOME, INC.(CNSY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1095981 CNSY stock profile & AI dashboard →

13F Pro Quality Score

10.3/100

Rank #2,909 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CNSY Scores 10/100

exact factor attribution · 2026-09-11

CNSY's composite is held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.4 pts

58th pct

Shareholder dilution

-2.0 pts

10th pct

Earnings growth

-2.2 pts

5th pct

Earnings quality

-2.7 pts

23th pct

Capital efficiency

-4.9 pts

1th pct

Profitability

-6.5 pts

7th pct

Free cash flow

-6.6 pts

6th pct

Scale

-6.8 pts

5th pct

Revenue growth

-8.4 pts

8th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CNSY Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CERENOME, INC. (CNSY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CNSY at 10.3/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), CERENOME, INC. reports quarterly revenue of $411.0K, net income of $-9.0M, free cash flow of $-7.6M. Top institutional holders of CNSY by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. CNSY trades on the Nasdaq exchange and files with the SEC under CIK 1095981. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNSY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CERENOME, INC. directly from SEC EDGAR. CERENOME, INC.'s 13F Pro composite quality score has ranged between 9 and 12 since 2026, currently 10.3 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$411.0K

Net Income

Q2 2026

$-9.0M

Free Cash Flow

Q2 2026

$-7.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-10.5% YoY

$5.2MFY 2025

FY22 —FY23 $4.9MFY24 $5.8MFY25 $5.2M

Net Income

-72.5% YoY

$-22.4MFY 2025

FY22 $-20.3MFY23 $-13.3MFY24 $-13.0MFY25 $-22.4M

Operating Income

-4.1% YoY

$-15.3MFY 2025

FY22 $-19.7MFY23 $-13.3MFY24 $-14.7MFY25 $-15.3M

EPS (Diluted)

+87.6% YoY

$-0.29FY 2025

FY22 $-6.03FY23 $-4.24FY24 $-2.34FY25 $-0.29

Total Assets

+146.1% YoY

$16.3MFY 2025

FY22 $23.9MFY23 $11.4MFY24 $6.6MFY25 $16.3M

Total Debt

—FY 2025

FY22 $5.4MFY23 $4.0MFY24 —FY25 —

Op. Cash Flow

-96.8% YoY

$-20.8MFY 2025

FY22 $-13.0MFY23 $-12.9MFY24 $-10.6MFY25 $-20.8M

Free Cash Flow

-94.8% YoY

$-20.8MFY 2025

FY22 —FY23 $-13.0MFY24 $-10.7MFY25 $-20.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.2M -10.5%	$5.8M +18.5%	$4.9M	—	—	—
Net Income	$-22.4M -72.5%	$-13.0M +2.5%	$-13.3M +34.3%	$-20.3M -51.3%	$-13.4M -62.6%	$-8.2M
Operating Income	$-15.3M -4.1%	$-14.7M -10.3%	$-13.3M +32.4%	$-19.7M -57.8%	$-12.5M -30.3%	$-9.6M
EPS (Diluted)	$-0.29 +87.6%	$-2.34 +44.8%	$-4.24 +29.7%	$-6.03 -943.3%	$-0.58	—
Total Assets	$16.3M +146.1%	$6.6M -41.8%	$11.4M -52.3%	$23.9M +8.6%	$22.0M +81.6%	$12.1M
Total Debt	—	—	$4.0M -26.3%	$5.4M -18.4%	$6.6M +4.4%	$6.3M
Operating Cash Flow	$-20.8M -96.8%	$-10.6M +17.9%	$-12.9M +0.9%	$-13.0M -26.2%	$-10.3M -21.9%	$-8.4M
Free Cash Flow	$-20.8M -94.8%	$-10.7M +17.8%	$-13.0M	—	—	—

Get alerted when CNSY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CERENOME, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CNSY

VANGUARD CAPITAL MANAGEMENT LLC
$1.3M304,745 sh
BlackRock, Inc.
$419.4K95,983 sh
GEODE CAPITAL MANAGEMENT, LLC
$332.9K76,155 sh
VANGUARD FIDUCIARY TRUST CO
$161.1K36,868 sh
Ashton Thomas Private Wealth, LLC
$149.9K34,306 sh
CITADEL ADVISORS LLC
$111.9K25,597 sh
NORTHERN TRUST CORP
$67.8K15,516 sh
Virtu Financial LLC
$67.0K15,343 sh
HRT FINANCIAL LP
$50.0K11,612 sh
WELLS FARGO & COMPANY/MN
$26.9K6,156 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.3M	304,745
BlackRock, Inc.	$419.4K	95,983
GEODE CAPITAL MANAGEMENT, LLC	$332.9K	76,155
VANGUARD FIDUCIARY TRUST CO	$161.1K	36,868
Ashton Thomas Private Wealth, LLC	$149.9K	34,306
CITADEL ADVISORS LLC	$111.9K	25,597
NORTHERN TRUST CORP	$67.8K	15,516
Virtu Financial LLC	$67.0K	15,343
HRT FINANCIAL LP	$50.0K	11,612
WELLS FARGO & COMPANY/MN	$26.9K	6,156

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CNSY on your watchlist

Track score changes the day CERENOME, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CNSY a good stock to buy?

13F Pro's AI-powered analysis of CERENOME, INC. (CNSY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNSY are available on the CNSY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CNSY is classified as a small company.

Which hedge funds own CNSY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNSY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CERENOME, INC.'s investment landscape.